Catalyst overview
Research summary
This catalyst tracks a Phase 1 update for CDX-622 in Inflammatory disease. The expected timing is based on the latest available company guidance and may change.
11/20/24- First patient dosed. 2/27/25- Enrollment ongoing. 10/30/25- Initial positive results reported. Report data from Part 2 & Part 3 in Q3 2026. 11/10/25:- Detailed Ph1 Part 1 data reported; Part 2 enrollment ongoing; data expected Q3 2026. 02/25/26:- Phase 1 healthy-volunteer study enrollment completed; multiple-dose and subcutaneous data expected Q3 2026. 05/07/26:- Multi-part healthy-volunteer Ph1 enrollment complete; multiple-dose and SubQ data still anticipated Q3 2026. 06/14/26:- EAACI Phase 1 results positive. Phase 1b proof-of-mechanism asthma study ongoing. 08/06/26:- Ph1 results positive; asthma POM study ongoing; expansion includes allergic rhinitis and food allergy.
Verification
Confirm timing and program details against the company announcement or filing.